Fortress Biotech (NASDAQ:FBIOP) (NASDAQ: FBIOP) is a biopharmaceutical company that acquires, develops and commercializes innovative therapeutics for the treatment of patients with serious diseases. Operating as a biotech accelerator, Fortress Biotech partners with experienced management teams to advance products from early-stage discovery through regulatory approval and commercial launch. Its diversified portfolio spans multiple therapeutic areas, including oncology, rare diseases, dermatology, ophthalmology and neuromuscular disorders.
The company’s business model centers on establishing and funding product-centric subsidiary companies, each focused on a specific drug candidate or therapy. By providing financial resources, operational support and strategic guidance, Fortress Biotech enables these subsidiaries to progress clinical programs and engage with regulatory authorities. This approach allows for nimble decision‐making at the subsidiary level, while leveraging Fortress Biotech’s corporate infrastructure for shared services such as investor relations, legal and finance.
Founded in 2006 and headquartered in Bay Harbor Islands, Florida, Fortress Biotech was established by Dr. Lindsay A. Rosenwald, who serves as Chairman. The company is led by David F. Butters, President and Chief Executive Officer, and supported by a management team with extensive experience in drug development and commercialization. Fortress Biotech’s network of subsidiaries operates primarily in the United States, with certain clinical and manufacturing activities conducted through international collaborations and contract research organizations.
Over the years, Fortress Biotech has successfully advanced multiple product candidates into clinical trials and regulatory review, demonstrating its capabilities as a biotech incubator. The company continues to expand its pipeline through in-licensing agreements, strategic partnerships and targeted acquisitions, with the objective of delivering novel therapies to patients while creating long-term value for shareholders.
